abstract |
The present invention provides novel oligonucleotide-based compounds that individually provide specific immune response profiles through interaction as agonists of TLR9. A TLR9 agonist according to the present invention is characterized by specific and unique chemical modifications, which provide its characteristic immune response activation profile. |